ARTICLE | Clinical News
ORI-1001 topical gel: Began Phase I testing
September 10, 2001 7:00 AM UTC
Origenix Technologies Inc., Montreal, Quebec Product: ORI-1001 topical gel Business: Infectious diseases Therapeutic category: Antisense Target: E1 region of the human papillomavirus (HPV) Description...